Bentley Laboratories Receives FDA CGMP Warning Letter Citing OOS Investigation Failures and Unapproved Drugs

Bentley Laboratories LLC is operating under formal FDA scrutiny after a warning letter dated September 17, 2026 identified CGMP violations significant enough to render its OTC drug products adulterated under 21 U.S.C. 351(a)(2)(B). For QA directors and plant heads at contract OTC manufacturers, the letter signals that OOS investigation depth and unapproved drug labeling remain active inspection priorities at CDER.

FDA inspectors examined the Edison, NJ facility (FEI 2244819) from March 16 to 27, 2026, citing deficiencies under 21 CFR Parts 210 and 211. The primary CGMP violation centers on Bentley's failure to thoroughly investigate out-of-specification laboratory results per 21 CFR 211.192. Specifically, the firm did not adequately identify root causes for OOS assay results at the 24-month stability timepoint, nor did it evaluate the market impact of affected batches. A separate OOS pH result at the 36-month stability timepoint was also inadequately investigated, with the firm's CAPA response deemed insufficient.

Beyond CGMP, the inspection review of product labeling produced a second category of violations. Two products, Geologie Acne Control Body Wash and Perricone MD Acne Relief Maximum Strength Spot Gel, were identified as unapproved new drugs under section 505(a) of the FD&C Act and misbranded under section 502(ee). Introducing either product into interstate commerce is prohibited under sections 301(a) and 301(d), a finding that carries direct supply-chain consequences for any retailer or brand partner currently holding inventory.

FDA acknowledged receipt of Bentley's April 21, 2026 Form FDA 483 response and subsequent correspondence but found the corrective actions inadequate. The agency's explicit warning that failure to address violations may result in seizure or injunction, without further notice, sets a measurable compliance deadline that regulatory affairs leads should track against their own CAPA closure timelines.

Bentley's path to resolution will require documented root-cause analysis for each cited OOS event, a defensible market-impact assessment for distributed batches, and a clear regulatory strategy for the two products flagged as unapproved new drugs before FDA considers the matter closed.

Source: FDA Center for Drug Evaluation and Research (CDER) via FDA.gov Warning Letters database, September 29, 2026.